SE512531C2 - Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur - Google Patents

Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Info

Publication number
SE512531C2
SE512531C2 SE9703191A SE9703191A SE512531C2 SE 512531 C2 SE512531 C2 SE 512531C2 SE 9703191 A SE9703191 A SE 9703191A SE 9703191 A SE9703191 A SE 9703191A SE 512531 C2 SE512531 C2 SE 512531C2
Authority
SE
Sweden
Prior art keywords
astaxanthin
disorders
mammalian muscle
prophylactic
xanthophyll
Prior art date
Application number
SE9703191A
Other languages
English (en)
Swedish (sv)
Other versions
SE9703191L (sv
SE9703191D0 (sv
Inventor
Aake Lignell
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE512531(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Priority to SE9703191A priority Critical patent/SE512531C2/sv
Publication of SE9703191D0 publication Critical patent/SE9703191D0/xx
Priority to US09/485,704 priority patent/US6245818B1/en
Priority to AT98943128T priority patent/ATE230985T1/de
Priority to DE69810784T priority patent/DE69810784T2/de
Priority to PL98338982A priority patent/PL338982A1/xx
Priority to ES98943128T priority patent/ES2191329T3/es
Priority to EP98943128A priority patent/EP1011653B1/fr
Priority to JP2000508354A priority patent/JP3660244B2/ja
Priority to CA002299366A priority patent/CA2299366C/fr
Priority to AU90989/98A priority patent/AU727349B2/en
Priority to PCT/SE1998/001526 priority patent/WO1999011251A1/fr
Priority to DK98943128T priority patent/DK1011653T3/da
Publication of SE9703191L publication Critical patent/SE9703191L/
Priority to NO20001087A priority patent/NO20001087D0/no
Publication of SE512531C2 publication Critical patent/SE512531C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)
SE9703191A 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur SE512531C2 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
PCT/SE1998/001526 WO1999011251A1 (fr) 1997-09-04 1998-08-26 Medicament pour l'amelioration de la duree de la fonction musculaire ou le traitement de troubles ou de maladies musculaires
DK98943128T DK1011653T3 (da) 1997-09-04 1998-08-26 Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser
ES98943128T ES2191329T3 (es) 1997-09-04 1998-08-26 Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
CA002299366A CA2299366C (fr) 1997-09-04 1998-08-26 Utilisation de xanthophylles pour ameliorer la duree de la fonction musculaire ou pour traiter des troubles musculaires ou des maladies
DE69810784T DE69810784T2 (de) 1997-09-04 1998-08-26 Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel-funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
PL98338982A PL338982A1 (en) 1997-09-04 1998-08-26 Drug for improving duration of muscle action or for treating muscular disorders or diseases
US09/485,704 US6245818B1 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
EP98943128A EP1011653B1 (fr) 1997-09-04 1998-08-26 Utilisation de xanthophylles dans des medicaments pour l'amelioration de la duree de la fonction musculaire ou le traitement de troubles ou de maladies musculaires
JP2000508354A JP3660244B2 (ja) 1997-09-04 1998-08-26 筋肉機能の持続時間を改善し、または筋肉障害もしくは疾患を治療するための医薬品
AT98943128T ATE230985T1 (de) 1997-09-04 1998-08-26 Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
AU90989/98A AU727349B2 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
NO20001087A NO20001087D0 (no) 1997-09-04 2000-03-02 Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Publications (3)

Publication Number Publication Date
SE9703191D0 SE9703191D0 (sv) 1997-09-04
SE9703191L SE9703191L (sv) 1999-03-05
SE512531C2 true SE512531C2 (sv) 2000-03-27

Family

ID=20408142

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Country Status (13)

Country Link
US (1) US6245818B1 (fr)
EP (1) EP1011653B1 (fr)
JP (1) JP3660244B2 (fr)
AT (1) ATE230985T1 (fr)
AU (1) AU727349B2 (fr)
CA (1) CA2299366C (fr)
DE (1) DE69810784T2 (fr)
DK (1) DK1011653T3 (fr)
ES (1) ES2191329T3 (fr)
NO (1) NO20001087D0 (fr)
PL (1) PL338982A1 (fr)
SE (1) SE512531C2 (fr)
WO (1) WO1999011251A1 (fr)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US7078040B2 (en) 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
US6900324B2 (en) 2000-09-07 2005-05-31 Astrazeneca Ab Process for preparing a substituted imidazopyridine compound
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
CN101845009B (zh) 2002-07-29 2012-10-03 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
AU2002329108A1 (en) * 2002-09-03 2004-03-29 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Method of preparing chitosan microcapsules of astaxanthin and product thus obtained
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1974730A1 (fr) * 2003-11-03 2008-10-01 AstraZeneca AB Dérivés d'imidazo[1,2-a]pyridine pour l'utilisation dans le traitement des troubles du sommeil provoqués par un reflux gastro-oesophagien silencieux
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
JPWO2005074907A1 (ja) * 2004-02-04 2007-09-13 富士化学工業株式会社 遺伝子発現調節剤
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
EP1750723A1 (fr) * 2004-04-14 2007-02-14 Hawaii Biotech, Inc. Analogues ou derives de carotenoide pour inhiber et reduire l'inflammation
WO2006039685A2 (fr) * 2004-10-01 2006-04-13 Hawaii Biotech, Inc. Procedes permettant la synthese d'intermediaires chiraux de carotenoides, d'analogues de carotenoides et de derives de carotenoides
JP5196708B2 (ja) * 2005-02-04 2013-05-15 富士化学工業株式会社 アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
CA2610502A1 (fr) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction de l'activation du complement et de l'inflammation dans une lesion tissulaire a l'aide de carotenoides, d'analogues de carotenoides ou de derives de carotenoides
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
US10867701B1 (en) 2010-06-28 2020-12-15 Heinrich Anhold System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) * 2013-04-30 2016-05-25 株式会社ダイセル 抗疲労用組成物
CN112057420A (zh) * 2020-09-21 2020-12-11 中国科学院烟台海岸带研究所 一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558372B1 (fr) 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja) * 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH0665033A (ja) 1992-08-11 1994-03-08 Lion Corp 口腔用組成物
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
US5886053A (en) 1995-02-03 1999-03-23 Basf Aktiengesellschaft Use of carotenoids for producing drugs for the treatment of dermatoses
JPH09124470A (ja) 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物

Also Published As

Publication number Publication date
NO20001087L (no) 2000-03-02
DE69810784T2 (de) 2003-11-13
JP2001514215A (ja) 2001-09-11
SE9703191L (sv) 1999-03-05
EP1011653A1 (fr) 2000-06-28
DE69810784D1 (de) 2003-02-20
JP3660244B2 (ja) 2005-06-15
PL338982A1 (en) 2000-12-04
ATE230985T1 (de) 2003-02-15
WO1999011251A1 (fr) 1999-03-11
CA2299366A1 (fr) 1999-03-11
EP1011653B1 (fr) 2003-01-15
DK1011653T3 (da) 2003-05-26
CA2299366C (fr) 2008-04-22
SE9703191D0 (sv) 1997-09-04
NO20001087D0 (no) 2000-03-02
AU727349B2 (en) 2000-12-14
US6245818B1 (en) 2001-06-12
AU9098998A (en) 1999-03-22
ES2191329T3 (es) 2003-09-01

Similar Documents

Publication Publication Date Title
SE512531C2 (sv) Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
JP3537832B2 (ja) 代謝を増強し酸化ストレスを防止するための食物組成物
JP2925326B2 (ja) ヒトの窒素保持の促進方法
US10821153B2 (en) Composition for improving muscular function or for enhancing exercise performance comprising vigna angularis var. angularis
US20210128664A1 (en) Agent for Activating Astrocyte Glucose Metabolism
EP2859896B1 (fr) Compositions pharmaceutiques pour le traitement des troubles musculaires
US20210369663A1 (en) Compositions and methods using a combination of curcumin and an omega-3 fatty acid for cellular energy
SE511237C2 (sv) Användning av åtminstone en typ av xantofyller för framställning av ett humant eller verinärmedicinskt läkemedel för profylaktisk behandling av mastit hos däggdjursmammor
US20110160136A1 (en) Polyphenols for the treatment of cartilage disorders
US8673287B2 (en) Anti-obesity composition containing acacia bark derivative
CN112512543A (zh) 用于预防、改善或治疗肌肉疾病或用于改善肌肉功能的包含海菊提取物的组合物
US10507224B2 (en) Composition including kirenol or siegesbeckia herba extract for muscle function improvement or exercise ability enhancement
US20080312149A1 (en) Health Food and Pharmaceutical Composition for Amelioration of Disease Induced by Metabolic Disorder in Cartilage
CN114601825B (zh) 一种肠道菌群代谢物吲哚-3-甲醛在防治动脉粥样硬化中的应用
JP2011207815A (ja) 抗酸化ストレス剤
KR20100016096A (ko) 제니스테인의 신규 용도
WO2020122373A1 (fr) Composition comprenant un extrait de glycyrrhiza uralensis en tant que principe actif pour la prévention, l'atténuation ou le traitement du syndrome d'hypogonadisme d'apparition tardive
US20190183811A1 (en) Composition containing squalene for improving muscle function and preventing muscle damage
WO2019146735A1 (fr) Composition pour prévention ou amélioration de la douleur nociceptive
CN117482099B (zh) 木通皂苷d在制备抗骨骼肌萎缩、肌病药物中的应用
US20220088106A1 (en) Composition comprising cudrania tricuspidate as effective component for alleviating, treating, or preventing muscular diseases, or improving muscule functions
KR20190003570A (ko) 안전한·안정된 플라스마로겐과 그 제제 및 인지증의 미병 상태의 판정 방법
KR102467123B1 (ko) 갯질경 추출물을 포함하는 지구력 증진용 조성물
Ismael et al. Effects of Cisplatin on Glycemic Control and Lipid Profile in Male Albino Rats Role of Propolis
US8128969B2 (en) Hypoglycemic composition containing acacia bark derivative

Legal Events

Date Code Title Description
NUG Patent has lapsed